Adlai Nortye Starts Phase III Trial of Pan- PI3K Inhibitor in Head and Neck Carcinoma

Adlai Nortye, a Hangzhou-New Jersey biopharma, has dosed the first patient in a global Phase III trial of Buparlisib at the Shanghai Eastern Hospital Medical Center . The trial will test Buparlisib, an oral pan-PI3K inhibitor, as a second-line therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients must have disease that progressed after a previous PD-1/PD-L1 treatment. Adlai Nortye said the trial is the first global multicenter Phase III trial of a PI3K inhibitor as an HNSCC therapy. More details.... Share this with colleagues: // //